CyclinD1, a prominent prognostic marker for endometrial diseases

Diagnostic Pathology

Volumn 8, Issue 1, 2013, Pages

  Liang, Shuo ^a   Mu, Kun ^a,b   Wang, Yan ^a,b   Zhou, Zhiqiang ^a,b   Zhang, Juan ^b   Sheng, Yan ^a   Zhang, Tingguo ^a,b  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

CyclinD1; Endometrial cancer; Prognostic markers; Survival analysis

Indexed keywords

CCND1 PROTEIN, HUMAN; CYCLIN D1; TUMOR MARKER;

ADENOCARCINOMA; ADULT; ARTICLE; BIOPSY; CHEMISTRY; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM TUMOR; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEOPLASM; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME; UPREGULATION;

ADENOCARCINOMA, CLEAR CELL; ADULT; BIOPSY; CARCINOMA, ENDOMETRIOID; CHI-SQUARE DISTRIBUTION; CYCLIN D1; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84881405151     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-8-138     Document Type: Article

References (21)

1. Colombo N, Preti E, Landoni F, Carinelli S, Colombo A, Marini C, Sessa C, ESMO Guidelines Working Group Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011, 22(suppl 6):vi35-vi39. ESMO Guidelines Working Group.
2. Weinhold N, Johnson DC, Chubb D, Chen B, Försti A, Hosking FJ, Broderick P, Ma YP, Dobbins SE, Hose D, Walker BA, Davies FE, Kaiser MF, Li NL, Gregory WA, Jackson GH, Witzens-Harig M, Neben K, Hoffmann P, Nöthen MM, Mühleisen TW, Eisele L, Ross FM, Jauch A, Goldschmidt H, Houlston RS, Morgan GJ, Hemminki K. The CCND1 c.870G > A polymorphism is a risk factor for t (11;14)(q13;q32) multiple myeloma. Nat Genet 2013, 45(5):522-5. 10.1038/ng.2583, 23502783.
3. Bosch F, Jares P, Campo E, Lopez-Guillermo A, Piris MA, Villamor N, Tassies D, Jaffe ES, Montserrat E, Rozman C. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 1994, 84:2726-2732.
4. Yang WI, Zukerberg LR, Motokura T, Arnold A, Harris NL. Cyclin D1 (Bcl-1, PRAD1) protein expression in low-grade B-cell lymphomas and reactive hyperplasia. Am J Pathol 1994, 145:86-96. 1887308, 7518196.
5. Yu W, Jin FZ, Ying YL, Gui PH. An analysis of Cyclin D1, Cytokeratin 5/6 and Cytokeratin 8/18 expression in breast papillomas and papillary carcinomas. Diagn Pathol 2013, 8:8. 10.1186/1746-1596-8-8, 3571902, 23327593.
6. Hong A, Davies S, Stevens G, Lee CS. Cyclin D1 overexpression in AIDS-related and classic Kaposi sarcoma. Appl Immunohistochem Mol Morphol 2004, 12:26-30.
7. Horvai AE, Kramer MJ, O'Donnell R. Beta-catenin nuclear expression correlates with cyclin D1 expression in primary and metastatic synovial sarcoma: a tissue microarray study. Arch Pathol Lab Med 2006, 130:792-798.
8. Kim JK, Diehl JA. Nuclear cyclin D1: an oncogenic driver in human cancer. J Cell Physiol 2009, 220:292-296. 10.1002/jcp.21791, 2874239, 19415697.
9. Lin L, Hicks D, Xu B, Sigel JE, Bergfeld WF, Montgomery E, Fisher C, Hartke M, Tubbs R, Goldblum JR. Expression profile and molecular genetic regulation of cyclin D1 expression in epithelioid sarcoma. Mod Pathol 2005, 18:705-709. 10.1038/modpathol.3800349, 15578074.
10. FIGO Announcements FIGO stages-- 1988 revision. Gynecol Oncol 1989, 35:125-7. FIGO.
11. Kurman RJ, Zaino RJ, Norris HJ. Endometrial Carcinoma. Blaustein's Pathology of the Female Genital Tract 1994, 439-86. New York: Springer, Kurman RJ, 4.
12. Zhou GY, Gao P. The derivative of molecular pathology--the inevitable development track of the pathology. Journal of Shandong University (Health Sciences) 2011, 49:63-66.
13. Christopherson WM, Alberhasky RC, Connelly PJ. Carcinoma of the endometrium: I. A clinicopathologic study of clear-cell carcinoma and secretory carcinoma. Cancer 1982, 49:1511-23. 10.1002/1097-0142(19820415)49:8<1511::AID-CNCR2820490802>3.0.CO;2-6, 7066860.
14. Lauchlan SC. Tubal (serous) carcinoma of the endometrium. Arch Pathol Lab Med 1981, 105:615-8.
15. Lauchlan SC. The secondary mullerian system revisited. Int J Gynecol Pathol 1994, 13(1):73-9. 10.1097/00004347-199401000-00009, 8112958.
16. Motokura T, Bloom T, Kim HG, Jüppner H, Ruderman JV, Kronenberg HM, Arnold A. A novel cyclin encoded by a bc-l 1-linked candidat e oncogene. Nature 1991, 350:512. 10.1038/350512a0, 1826542.
17. Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev 1993, 7:812-21. 10.1101/gad.7.5.812, 8491378.
18. Aquino G, Franco R, Ronconi F, Anniciello A, Russo L, De Chiara A, Panico L. Peripheral T-cell Lymphoma with Cyclin D1 overexpression: a case report. Diagn Pathol 2012, 7:79. 10.1186/1746-1596-7-79, 3475098, 22770229.
19. Sun Y, Luo D, Liao DJ, et al. CyclinD1 protein plays different roles in modulating chemoresponses in MCF7 and MDA-MB231 cells. J Carcinog 2012, 11:12. 10.4103/1477-3163.100401, 3516383, 23233819.
20. Mao X, Orchard G, Vonderheid EC, Nowell PC, Bagot M, Bensussan A, Russell-Jones R, Young BD, Whittaker SJ. Heterogeneous abnormalities of CCND1 and RB1 in primary cutaneous T-Cell lymphomas suggesting impaired cell cycle control in disease pathogenesis. J Invest Dermatol 2006, 126(6):1388-95. 10.1038/sj.jid.5700224, 16614728.
21. Dekanić A, Dintinjan RD, Budisavljević I, Pećanić S, Butorac M, Jonjić N. Strong nuclear EGFR expression in colorectal carcinomas is associated with cyclin-D1 but not with gene EGFR amplification. Diagn Pathol 2011, 6:108. 10.1186/1746-1596-6-108, 3225321, 22050898.